scPharmaceuticals Inc. Stock price

Equities

SCPH

US8106481059

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
5.02 USD -0.20% Intraday chart for scPharmaceuticals Inc. -10.04% -19.94%
Sales 2024 * 40.03M Sales 2025 * 97.75M Capitalization 181M
Net income 2024 * -58M Net income 2025 * -26M EV / Sales 2024 * 4.53 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.86 x
P/E ratio 2024 *
-3.41 x
P/E ratio 2025 *
-8.16 x
Employees 136
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.56%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.44%
1 week-9.86%
Current month-16.45%
1 month-19.13%
3 months-21.41%
6 months-28.55%
Current year-19.78%
More quotes
1 week
4.84
Extreme 4.84
5.33
1 month
4.84
Extreme 4.84
6.28
Current year
4.74
Extreme 4.74
6.60
1 year
4.63
Extreme 4.63
12.75
3 years
3.48
Extreme 3.48
12.75
5 years
2.44
Extreme 2.44
12.75
10 years
2.44
Extreme 2.44
18.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 16-12-31
Director of Finance/CFO 49 14-08-31
Chief Tech/Sci/R&D Officer - 17-01-31
Members of the board TitleAgeSince
Director/Board Member 78 13-12-31
Director/Board Member 62 17-11-20
Chief Executive Officer 61 16-12-31
More insiders
Date Price Change Volume
24-03-28 5.02 -0.20% 110 060
24-03-27 5.03 +2.44% 229,540
24-03-26 4.91 +1.03% 299,212
24-03-25 4.86 -6.00% 664,203
24-03-22 5.17 -3.90% 206,239

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for the treatment of edema in adult patients with congestive heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome. Its pipeline programs also include scCeftriaxone and scCarbapenem. Its scCeftriaxone is an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms. Its scCarbapenem program is an antibiotic used intravenously for the treatment of infections caused by gram-negative organisms.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.03 USD
Average target price
19.5 USD
Spread / Average Target
+287.67%
Consensus
  1. Stock
  2. Equities
  3. Stock scPharmaceuticals Inc. - Nasdaq